Impact of COVID-19 pandemic on cardiac rhythm management services: Views from the United Kingdom

Wern Yew Ding, MBBS,* James Cranley, MD,† David Begley, MD,‡ Archana Rao, MD,† Richard L. Snowdon, MD,‡ Greg Mellor, MD,† Dhiraj Gupta, MD*

From the *Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital NHS Foundation Trust, Liverpool, United Kingdom, †Royal Papworth Hospital, Cambridge, United Kingdom, and ‡Liverpool Heart & Chest Hospital NHS Foundation Trust, Liverpool, United Kingdom.

BACKGROUND Effects of the COVID-19 pandemic on cardiac rhythm management (CRM) services remain poorly quantified.

OBJECTIVE To describe the impact of COVID-19 on specialist CRM centers in the United Kingdom (UK).

METHODS Two-center study involving the Liverpool Heart and Chest Hospital NHS Foundation Trust and Royal Papworth Hospital NHS Foundation Trust. The first nationwide lockdown lasted from April to July 2020 and the second from December 2020 to March 2021.

RESULTS Compared to the pre-pandemic period, pandemic 1 (April–July 2020) was associated with a 52.2% reduction in electrophysiology (EP) procedures (P = .003), 32.7% reduction in device procedures (P = .003), and 36.8% decrease in CRM referrals (P < .001). There was also a 13.4% increase in the use of conscious sedation (CS) (P < .001) and day-case procedures for EP (P = .003), with no change in day-case device procedures (P = .555). Corresponding numbers for pandemic 2 (August–November 2020) were a 0.7% increase in EP procedures (P = .925), 7.9% reduction in device procedures (P = .232), 13.9% decrease in referrals (P = .014), 5.5% increase in CS for EP (P = .009), 7.1% increase in day-case EP procedures (P < .001), and no change in day-case device procedures (P = .537). Corresponding numbers for pandemic 3 (December 2020–March 2021) were a 31.6% reduction in EP procedures (P = .001), 22.3% reduction in device procedures (P = .006), 8.4% decrease in referrals (P = .094), 11.0% increase in CS for EP (P < .001), 7.6% increase in day-case EP procedures (P = .003), and no change in day-case device procedures (P = .146). By the end of March 2021, the CRM waiting list was 167.8% pre-pandemic levels.

CONCLUSION During the COVID-19 pandemic, specialist centers in the UK were affected such that the number of procedures performed was greatly reduced in the initial period with latter improvements as better coping strategies were developed.

KEYWORDS COVID-19; Pandemic; Cardiology; Electrophysiology; Device; Cardiac rhythm management; Service; Impact; UK

(Heart Rhythm O2 2022;■:1–6) © 2022 Heart Rhythm Society. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction
The outbreak of COVID-19 has affected more than 200 million people worldwide, with 4 million confirmed deaths attributable to the disease.1 In addition to those infected, a large proportion of the population is also being affected by the reallocation of healthcare resources required to meet the pandemic’s demands, the impact of which may not be fully realized for many years.2–5 Overall, there has been a major impact on various healthcare services, though the effect has been heterogeneous.

Trends observed within cardiovascular services included dramatic reductions in healthcare utilization,4 including emergency care for ST-elevation myocardial infarction, heart failure, stroke, deep venous thrombosis, and pulmonary embolism.5,6 These may stem from patients’ reluctance to seek medical attention owing to fear of infection during hospital visits.7 Furthermore, cardiovascular procedural numbers were also reduced owing to a number of factors, including available hospital beds and resource reallocation to care for patients with COVID-19; reduced number of healthcare professionals owing to clinical reassignment, sickness, and the need to shield; and increased procedural times owing to added infection control measures.7

The effects of COVID-19 on cardiovascular services in specialist centers remain poorly quantified. Here, we aimed to describe the impact of the COVID-19 pandemic on cardiac rhythm management (CRM) service provision in specialist centers across the United Kingdom (UK).

Methods
Setting
The Liverpool Heart and Chest Hospital NHS Foundation Trust (LHCH) and Royal Papworth Hospital NHS
KEY FINDINGS

- The onset of the pandemic saw drastically reduced numbers of both cardiac rhythm management referrals received and procedures performed.
- Emergency procedure numbers also reduced, however, representing a reluctance of patients to present to hospital, as seen across a wide range of medical emergencies.
- As we developed a better understanding of the disease and adapted our services to cope with the pandemic, there were increased numbers of cardiac rhythm management referrals and procedures performed (though not to pre-pandemic levels), even during the second and third lockdowns in England when there were very high numbers of COVID-19 cases.

Foundation Trust (RPH) are 2 of the 3 largest CRM centers in the UK (Supplemental Figure 1). Both sites are specialist cardiorespiratory centers without accident and emergency departments or direct admission of unselected general medical patients.

Time periods

CRM activity was retrospectively analyzed for both centers between April 2019 and March 2021. For the purposes of this study, April 2019 to March 2020 was defined as the pre-pandemic period and used as a reference to which activity during the COVID-19 pandemic was compared. The time period from April 2020, to coincide with the first lockdown in the UK, which began on March 23, 2020 (Supplemental Figure 2), was defined as the pandemic period. The pandemic period was then divided into 3 separate 4-month periods reflecting the variation in COVID-19 cases nationally and the start and end of national lockdown periods: pandemic 1 (April–July 2020), pandemic 2 (August–November 2020), and pandemic 3 (December 2020–March 2021).

Data collection

Caseload data in terms of referral patterns, procedures, and waiting times relating to CRM activity were collected from institutional databases. Patients who were reviewed by a cardiac rhythm specialist and listed for a procedure were considered to be on the waiting list. CRM data across the UK were obtained from the National Institute for Cardiovascular Outcomes Research online database, which uses standardized data collection methods to collect information about all implanted cardiac devices and all patients receiving interventional procedures for management of cardiac rhythm disorders in the UK. COVID-19 data for the UK were obtained from https://coronavirus.data.gov.uk. No patient-level data were used. The research complied with the Declaration of Helsinki, the study protocol was approved by the ethics boards at both participating institutions, and all patients provided written informed consent for their procedures.

Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research.

Statistical analysis

Aggregate data are presented unless otherwise stated. Continuous variables are presented as mean ± standard deviation (SD) and compared using Student t test. Categorical variables are presented as count and percentage and are compared using the chi-squared test. A P value of less than .05 was considered statistically significant. Statistical analyses were performed using SPSS version 27 (IBM Corp, Armonk, NY).

Results

Burden of COVID-19

The burden of COVID-19 in the UK and specifically for Liverpool (LHCH) and Cambridge (RPH) is shown in Supplemental Figure 3. Overall trends were similar across both sites, with fewer COVID-19 in-patients during pandemic 2 than pandemics 1 and 3. LHCH and RPH have bed capacities of 187 and 300, respectively. RPH was under a greater strain from COVID-19 during pandemic 1 and pandemic 3, owing to planned regional load-leveling maneuvers (Figure 1). The percentage of beds used for COVID-19 patients at LHCH were 3.8%, 2.5%, and 5.3% during pandemic 1, pandemic 2, and pandemic 3, respectively. At RPH, corresponding numbers were 7.6%, 1.2%, and 11.3%.

CRM referrals and procedures performed

Early in the pandemic period, triage systems with similar criteria were introduced at both sites to prioritize patients based on clinical urgency (Table 1). During the pre-pandemic period, 597 ± 49 monthly referrals were received across both sites. A total of 202 ± 28 ablations and 261 ± 31 device procedures were performed per month. The monthly trends in total numbers of referrals and procedures performed at both sites across the study period are displayed in Figure 2. After the national lockdown that commenced on March 23, 2020, all elective CRM activity ceased for 6 weeks, in accordance with national policy at the time. Compared to the pre-pandemic period, pandemic 1 was associated with a decrease of 36.8% (377 ± 112, P < .001) in the number of CRM referrals and reduction of 52.2% (96 ± 83, P = .083) and 32.7% (176 ± 66, P = .003) in the number of EP and device procedures performed, respectively. While pandemic 2 was associated with a decrease of 13.9% (514 ± 60, P = .014) in the number of referrals, both EP (increase of 0.7%, 203 ± 25, P = .925) and device procedural numbers (decrease of 7.9%, 240 ± 17, P = .232) had returned to similar numbers to pre-pandemic. During pandemic 3, referral numbers were similar to pre-pandemic levels (547 ± 47, P = .094 for difference) while numbers of both EP and device procedures were again significantly reduced by 31.6% (138 ± 23, P = .001) and 22.3% (203 ± 33, P = .006), respectively.
During COVID-19, anesthetists were redeployed to intensive care units and COVID-19 duties, leading to loss of general anesthesia support for CRM procedures. Overall, there was an increase in the proportion of EP procedures that were performed under light CS during the pandemic period (Supplemental Figure 4). Pre-pandemic, an average of 127 ± 21 monthly EP procedures were performed under CS. Compared to the pre-pandemic period, there was an increase in the percentage of EP procedures that were performed under CS by 13.4% (70 ± 66, P < .001) in pandemic 1, 5.5% (139 ± 14, P = .009) in pandemic 2, and 11.0% (100 ± 6, P < .001) in pandemic 3.

**Day case vs overnight stay**
The percentage of EP procedures that were performed as day-case procedures (vs overnight stay) increased steadily through the pandemic (Supplemental Figure 5). Pre-pandemic, an average of 129 ± 25 monthly EP procedures was performed as day-case procedures. Compared to the pre-pandemic period, there was an increase in the number of EP procedures that were performed as day-case procedures by 5.4% (69 ± 59, P = .003) in pandemic 1, 7.1% (144 ± 16, P < .001) in pandemic 2, and 7.6% (98 ± 12, P = .003) in pandemic 3.

Pre-pandemic, an average of 166 ± 25 monthly device procedures was performed as day-case procedures. Compared to the pre-pandemic period, there was no significant change in the percentage of device procedures that were performed as day-case procedures (vs overnight stay) in pandemic 1 (P = .555), pandemic 2 (P = .537), or pandemic 3 (P = .146).

**Caseload and waiting list**
A breakdown of caseload of EP and device procedures at both sites is shown in Supplemental Figures 6 and 7, respectively. Notably, the number of implantable loop recorder implants declined significantly during the pandemic period. In contrast, the number of device extractions remained consistent throughout the 2-year period.

The number of patients on waiting lists for EP and device procedures was fairly consistent during the pre-pandemic period (Figure 3), with a mean of 631 ± 74 patients. However, this figure has risen dramatically during the pandemic such that by the end of March 2021, there were 1059 patients on the CRM waiting list across both sites (455 [282 EP; 173 devices] at LHCH and 604 [452 EP; 152 devices] at RPH). This represents a 67.8% increase above the pre-pandemic levels.

**Discussion**
In this multicenter study, we described the significant impact that the COVID-19 pandemic has had on CRM services in 2 large tertiary centers in England. The onset of the pandemic saw drastically reduced number of both referrals received and procedures performed. Emergency procedure numbers also reduced, however, representing a reluctance of patients to present to hospital, as seen across a wide range of medical emergencies. As we developed a better understanding of the disease and adapted our services to cope with the pandemic, there were increased numbers of CRM referrals and procedures performed (though not to pre-pandemic levels), even during the second and third lockdown in England when there were very high numbers of COVID-19 cases.

The effects of COVID-19 have also been reported in other cardiology services at district UK hospitals, where there were anecdotal reports of patients avoiding admission owing to fear of developing infection or concern that hospitals may be too overwhelmed to provide appropriate care. Nonetheless, it seems that CRM services have been more badly affected by the COVID-19 pandemic when compared with other cardiology services. The COVID-19 pandemic has had a similar impact on clinical activities relating to arrhythmias and EP in other parts of the world. In Italy, a survey of 104 physicians from 84 centers found that more than 95% and 75% of centers had a significant reduction in the number of elective pacemaker implantations and ablation, respectively, during the initial 2 months of the pandemic (March–April 2020) compared to the corresponding 2 months of the year 2019. There has been a reduction across all cardiology performance indicators, from referrals to investigations, diagnoses, and management, owing to a shift in focus to deal with the COVID-19 pandemic and patients’ reluctance to seek medical attention. Widespread adoption of clinical priority scoring which, quite appropriately, prioritizes those patients with life-threatening disease, may also exacerbate waits for patients with arrhythmia.
Table 1 Triage system at Liverpool Heart and Chest Hospital NHS Foundation Trust and Royal Papworth Hospital NHS Foundation Trust

<table>
<thead>
<tr>
<th>Category 1 (high risk)</th>
<th>Category 2 (intermediate risk)</th>
<th>Category 3 (Low risk)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Secondary prevention ICD or CRT-D</td>
<td>Primary prevention ICD for increased risk of SCD</td>
<td>Primary prevention ICD or CRT-D</td>
</tr>
<tr>
<td>PPM for high grade AV block</td>
<td>Generator changes for PPM / ICD / CRT-D at ERI</td>
<td>PPM for sinus node dysfunction</td>
</tr>
<tr>
<td>PPM for syncope and an approved indication for pacing</td>
<td>CRT-D / CRT-P for recurrent heart failure hospital admissions and an approved device indication</td>
<td>CRT-P for pacing-induced cardiomyopathy</td>
</tr>
<tr>
<td>Generator changes for PPM / ICD / CRT-D at EOL</td>
<td>ILR for recurrent or malignant syncope</td>
<td>LV lead revision in stable patient</td>
</tr>
<tr>
<td>Lead revision for fracture/dislocation leading to arrhythmia, hemodynamic compromise, inappropriate shock, and/or hospital admission</td>
<td>PPM / CRT prior to AV node ablation for AF and unstable heart failure</td>
<td>PPM / CRT prior to AV node ablation for AF and stable heart failure</td>
</tr>
<tr>
<td>Lead extraction in sepsis</td>
<td>Lead revision for fracture/dislocation leading to symptoms but low risk of arrhythmia, hemodynamic compromise, inappropriate shock, and/or hospital admission</td>
<td>ILR for arrhythmia monitoring or unexplained symptoms</td>
</tr>
<tr>
<td>VT ablation in medically refractory electrical storm</td>
<td>Ablation of complex tachycardia leading to syncope</td>
<td>SVT ablation</td>
</tr>
<tr>
<td>Ablation of wide complex tachycardia leading to syncope</td>
<td>Ablation of atrial arrhythmias with recurrent arrhythmias and heart failure with device in situ</td>
<td>AF ablation</td>
</tr>
<tr>
<td>Ablation of atrial arrhythmias with uncontrolled ventricular rate leading to decompensated heart failure despite maximum medical therapy</td>
<td>Ablation of atrial arrhythmias with recurrent AED visits and/or hospital admissions</td>
<td>Atrial tachycardia or atrial flutter ablation</td>
</tr>
<tr>
<td>Ablation of pre-excited AF</td>
<td>Secondary prevention ICD or CRT-D</td>
<td>Atrial fibrillation or atrial flutter ablation</td>
</tr>
<tr>
<td>LAA occlusion procedures</td>
<td>CRT-D for recurrent heart failure hospital admissions</td>
<td>Ablation of idiopathic VT or PVC</td>
</tr>
<tr>
<td>AV node ablation for coexisting arrhythmias and heart failure with device in situ</td>
<td>CRT-P for recurrent heart failure hospital admissions</td>
<td>AV node ablation in stable patient</td>
</tr>
<tr>
<td>Ablation of atrial arrhythmias with recurrent AED visits and/or hospital admissions</td>
<td>CRT-D for recurrent heart failure hospital admissions</td>
<td>Diagnostic EPS</td>
</tr>
</tbody>
</table>

AED = accident and emergency department; AF = atrial fibrillation; AV = atioventricular; CRT = cardiac resynchronization therapy; CRT-D = cardiac resynchronization therapy defibrillator; CRT-P = cardiac resynchronization therapy pacemaker; EOL = end of life; EPS = electrophysiology study; ERI = elective replacement indication; ICD = implantable cardioverter-defibrillator; ILR = implantable loop recorder; LAA = left atrial appendage; LV = left ventricular; PPM = permanent pacemaker; PVC = premature ventricular complex; SCD = sudden cardiac death; SVT = supraventricular; VT = ventricular tachycardia.

Impact on procedural delivery

The increase in waiting lists described above will necessitate a variety of additional strategies not only to prioritize high-risk patients but also to improve procedural capacity and efficiency while protecting a workforce already at high risk of burnout. Increased number of patients treated as a day case may help by reducing the need for already in-demand in-patient beds. Undertaking procedures without the need for general anesthesia may both facilitate day-case operation and reduce associated infection control risks. From our experience, we found that both these strategies were effective at dealing with some of the challenges imposed by the COVID-19 pandemic and will likely continue to have a role in the future.

Clinical training for physicians

The reduced levels of CRM activity have also had negative consequences on clinical training for physicians subspecializing in cardiac EP and/or devices such that the decreased procedural volume may jeopardize the preparedness of trainees for independent practice, thereby having implications on the future delivery of healthcare in this area. This is especially pertinent in light of the growing number of patients on the CRM waiting list—many of whom will have their treatment delayed by several years in the current climate.

Overall, though the COVID-19 pandemic has had an unprecedented detrimental impact on healthcare provision across the health service, and many of the conditions being treated with ablation are not immediately life-threatening, it may be argued that such patients “will have to wait.” However, when considering atrial fibrillation (AF) in particular, which not only is the most common reason for interventional CRM treatment but also is a condition with significant morbidity and associated healthcare costs, strategies will be required to reduce or mitigate the prolonged waiting times. It is well recognized that catheter ablation is more successful for paroxysmal than persistent AF, and a proportion of patients will transition to more persistent forms of arrhythmia during a prolonged time on the waiting list. Those already in persistent AF will expect their chances of maintaining sinus rhythm to drop further if allowed to continue in AF for a year or more. In fact, it has previously been suggested that patients with persistent AF of more than 2 years’ duration should not undergo ablation, and a significant number of patients could cross this threshold on the extended waiting lists. Because this study reports data from 2 specialist cardiac centers, it can be assumed that waiting lists in CRM departments in general hospitals where the impact of COVID-19 admissions has been higher will likely have increased by even greater proportions.

Furthermore, recent evidence suggests that there may be a mortality benefit in early rhythm control among patients with AF, and that catheter ablation may be superior to antiarrhythmic drugs as a first-line treatment. Translating this evidence base for an early interventional approach into clinical practice will be extremely challenging in the face of already overburdened waiting lists. Therefore, there is a need to recruit additional staff (anesthetists, technicians, and staff nurses) to facilitate the delivery of more CRM procedures and reduce the impact if a similar situation were to arise again.
globally, and certainly within the field of CRM, there has been incredible effort made to cope with the situation, including an increased use of digital health and telemedicine. Moving forward, these are likely to have significant benefits to clinical practice and the delivery of holistic care to patients.

Limitations
This study is limited by the small number of participating centers. Furthermore, as it only included UK centers and those without an accident and emergency department, these observations may not be generalized, though it is likely the trend was similar, given the reports from few other

Figure 2  Overview of cardiac rhythm management services at Liverpool Heart and Chest Hospital NHS Foundation Trust (LHCH) and Papworth Hospital over a 2-year period. CRM = cardiac rhythm management; EP = electrophysiology.

Figure 3  Number of patients on the waiting list for cardiac electrophysiology and device procedures at Liverpool Heart and Chest Hospital NHS Foundation Trust (LHCH) and Papworth Hospital over a 2-year period. EP = electrophysiology.
centers/countries. The impact of COVID-19 may have been underestimated in these centers, given the relatively low number of beds that were used to care for COVID-19 patients. Further, the clinical impact of these observations was beyond the scope of this study and not evaluated.

Conclusion
The COVID-19 pandemic has had a significant impact on CRM services at specialist centers in the UK. The number of procedures performed was greatly reduced in the initial period with latter improvements as better coping strategies were developed. However, the waiting lists for both EP and device procedures have continued to rise steadily. There is a need for greater efficiency in healthcare systems to deal with the impending challenge.

Funding Sources: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Disclosures: GM: Speaker for Bayer, Consulting fees from Medtronic & Boston Scientific. DG: Speaker for Bayer, BMS/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, Medtronic, Biosense Webster, and Boston Scientific. Proctor for Abbott. Research Grants from Medtronic, Biosense Webster, and Boston Scientific. WYD, JC, DB, AR, and RLS: None declared.

Data Availability Statement: The data underlying this article will be shared on reasonable request to the corresponding author. All authors attest they meet the current ICMJE criteria for authorship. The authors attest that the research reported has adhered to relevant ethical guidelines and that the authors are in compliance with the regulations of their institutional review boards on human studies and animal care and use committees, including obtaining patient consent where appropriate. Please see our information on Ethics in publishing.

Appendix
Supplementary data
Supplementary data associated with this article can be found in the online version at https://doi.org/10.1016/j.hroo.2022.05.013.

References